Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste

BACKGROUND: The introduction of the bispecific antibody emicizumab-kxwh has driven a paradigm shift in the management of patients with hemophilia A. Emicizumab-kxwh is gradually replacing factor VIII as the treatment of choice for prophylaxis. The requirement to dose emicizumab-kxwh by weight can dr...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Albini, Lesley, Dorholt, Mary, Gallucci, Lydia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387933/
https://www.ncbi.nlm.nih.gov/pubmed/36580124
http://dx.doi.org/10.18553/jmcp.2023.29.1.47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387933/
https://www.ncbi.nlm.nih.gov/pubmed/36580124
http://dx.doi.org/10.18553/jmcp.2023.29.1.47

Ejemplares similares